A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid
Phase of Trial: Phase I
Latest Information Update: 17 Jun 2017
At a glance
- Drugs SEL 212 (Primary) ; Pegadricase; Sirolimus
- Indications Gout; Hyperuricaemia
- Focus Adverse reactions
- Sponsors Selecta Biosciences
- 17 Jun 2017 Results assessing initial safety and impact on serum uric acid levels and anti-drug antibodies presented at the 18th Annual Congress of the European League Against Rheumatism.
- 06 Jun 2017 Data from this trial will be presented at the Annual European Congress of Rheumatology (EULAR 2017), according to a Selecta Biosciences media release.
- 26 Jan 2017 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History